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Abstract:  The ability to critique the literature and source
out relevant information to answer a clinical question is
a skill that is being introduced into the under-graduate
curricula of most health professions.  Posing a clinical
question on therapy, sourcing the literature, reviewing
critically what you find and then hopefully answering the
question is central to the evidence-based method.  The
very foundation of clinical teaching and clinical practice
will in the future rely on the “evidence-based method”.  A
checklist is the easiest and quickest way to review journal
articles.
Key Indexing Terms:  Therapy, chiropractic, evidence-
based method, clinical epidemiology, evidence-based
chiropractic, checklist.
INTRODUCTION
The ability to critique the literature and source out
relevant information to answer a clinical question is a
skill that is being introduced into the under-graduate
curricula of most health professions.  Posing a clinical
question, sourcing the literature, reviewing critically
what you find and then hopefully answering the clinical
question is generically known as “Evidence-based health
care”.  In our profession I prefer to see the label “Evidence-
based chiropractic”.
Generally speaking journal articles which address clinical
questions fall into one of four categories:
1. Therapy
2. Diagnostic tests
3. Causation
4. Prognosis
In this article I deal exclusively with therapy.  Therapy
means any treatment applied to gain a healing or preventive
response.  However, it should be noted that an article on
prevention has slightly different review criteria than the
ones found below.
A checklist is the easiest and quickest way to review
journal articles.  A checklist (Figure 1) has been
constructed from a number of key texts (1- 5).  Read the
checklist and if you have difficulty with any section
review the explanatory notes below.
HOW TO UNDERSTAND AND USE THE
CHECKLIST
1. a) Advantages of randomisation
There is no bias in the allocation to treatments
groups. This evens out the groups and removes
potential biases.
Study groups will tend to be comparable with
respect to all variables except for the interventions
being studied.  Baseline characteristics, and
confounding factors will be evenly distributed.
Randomisation is extremely important.  If there
was no randomisation discard the article.  It is
worth noting there are several methods of
randomisation, look for this detail in the paper.
b) Research design
Is the research design the correct method of
studying the question asked?  It may be that the
question could have been answered with a more
appropriately designed study.
This can usually be answered after a critical
appraisal of the study and a basic working
knowledge of research design.  For example, the
strengths and weaknesses of randomised controlled
trials, cohort studies, case-control studies, cross-
sectional studies, case series and so on.
2. a) Patient selection
The study group should be a representative sample
of the wider population of those with the condition.
Therefore, it is important that those selected are
not a biased group in some manner. (Known as
“Selection bias”).  For example, in the case of
chronic low back pain it would be wrong to have
too many males, smokers, labourers, aged persons
etc.  The population sampled should be found in
the methods and results section.
b) Patient follow up
All patients should be accounted for at the end of
the trial.  Drop outs need to be identified and an
explanation of their fate given.  Patients do not
usually drop out of a study for trivial reasons.
They may refuse to have the therapy, have got
worse, have been cured or simply moved town.  All
of these reasons are important factors which may
effect the results.  If the drop outs are not discussed
adequately, then establish how many there are,
add them to the treatment failure list and re-
calculate the results.  Similarly add them to the53
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CHECKLIST AND WORKSHEET AS A GUIDE FOR
EVALUATING AN ARTICLE ABOUT THERAPY
Article title:  _____________________________________________________________
_______________________________________________________________________
Authors:   _______________________________________________________________
Publication details:   _______________________________________________________
Circle
1. a) Was the assignment of patients to treatment randomised? yes no ?
b) Was the research design fundamentally sound ? yes no ?
IF SO PROCEED TO Q2, IF NOT DISCARD STUDY!
2. Were all patients entered into the trial properly accounted
for and attributed at its conclusion? ie.
a) Was patient selection appropriate? yes no ?
b) Was follow up complete? yes no ?
c) Were patients analysed in the groups to which they were assigned? yes no ?
3. Were the patients blinded to which treatment they received? sb yes no ?
Were clinicians blinded to treatments given? db yes no ?
Were other key study personnel blinded as well? obs. bias yes no ?
4. Were both groups similar at baseline? ie
a) Demographic data (table?) yes no ?
b) Prognostic factors (stratified?) yes no ?
c) General health questions? yes no ?
If not, were the statistics adjusted to account for this? yes no ?
5. a) Was the eligibility criteria for the entry to the trial appropriate? yes no ?
b) Was the sample size calculated before trial commencement? yes no ?
6. Were all spectrums of disease represented in the sample? yes no ?
7. Were the interventions used appropriate ie.
a) Were they sensible and described adequately? yes no ?
b) Are they affordable? yes no ?
c) Are they available? yes no ?
d) Was there a placebo used? yes no ?
e) Was there a non-treatment group (natural history)? yes no ?
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Figure 1.
8. Were the groups “treated equally”. yes no ?
9. Was there any co-intervention? yes no ?
Was there any contamination? yes no ?
Did patients comply with treatment regimes and instructions? yes no ?
10. Were the instruments of measurement used:
a) reasonable and adequate for all clinically important outcomes? yes no ?
b) reliable and valid yes no ?
11. Was normal defined? yes no ?
12. a) Was there sufficient follow up? yes no ?
b) Were adverse effects documented? yes no ?
13. How large was the treatment effect? ie
a) Was it statistically significant? yes no ?
b) Was it clinically significant? yes no ?
c) Was the difference biologically plausible? yes no ?
14. How precise was the estimate of effect? ie.
a) Was sufficient sample size used? yes no ?
b) Were confidence intervals given? yes no ?
c) Was there any data dredging? yes no ?
15. Were the limitations of the study discussed adequately? yes no ?
16. Were there any other biases operating, and if so in what direction? yes no ?
17. Can the results be applied to my patient care? yes no ?
18. a) Is the treatment efficacious? yes no ?
b) Is it effective? yes no ?
Conclusion:   ____________________________________________________________
_______________________________________________________________________
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“cured” list and do likewise.  If this process does
not alter the outcome of the trial then you may
overlook the drop outs.
c) Intention to treat analysis
Patients should be analysed as being part of the
group to which they were originally allocated
during the randomisation process.  This is known
as “intention to treat analysis”.  This strategy
preserves the integrity of the randomisation
process.  For example if we exclude non-compliant
patients (even those who did not receive any
treatment) we leave behind a group who may have
been destined to do better than drop outs.  Intention
to treat analysis prevents systematic exclusion of
drop outs from the results, thereby better reflecting
the real life outcome of the intervention.
3. Blinding
a) A single blind trial is where the patient is unaware
of the treatment they are receiving, e.g. placebo or
drug.  A double blind trial has patient blinding and
in addition the treating doctor is also blinded to
the treatment received.  This is relatively simple
with drugs but impossible with manual therapy
such as manipulation.
However, it is important to blind the assessors of
outcome and initial assessment in all trials of this
nature.  If not, these assessors may inadvertently
influence the outcome by comments made to the
patient, or a preference for a particular intervention.
This is called observer bias.
The lack of blinding in trials of non-drug therapies
imposes an extra burden on the researcher to
ensure that those responsible for the delivery of
the treatment are competent and able to provide a
consistent level of care.  For example, in a trial
comparing manipulation with mobilisation, it
would be important for the practitioners to be
equally skilled at their craft and have equal
enthusiasm for the intended outcome.
4. Baseline data
a) Similarity of all treatment groups is important.
The authors should provide a table of demographic
data demonstrating that all treatment groups had
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similar demographics.  Of course, randomisation
usually takes care of this in large trials.  In the case
of smaller trials some special block randomisation
techniques can be used.  Usual baseline data
should include, age, gender and socio-economic
status.
b) Prognostic factors are other variables which should
be equal between the groups.  For instance, in a
trial on back pain, both groups should at baseline
have a similar mean disability score and chronicity.
Otherwise one groups prognosis may be worse at
the outset and bias the outcome.
c) General health status of groups should be similar.
This can be established with validated health
questionnaires such as the Sickness Impact Profile.
There should not be a significant difference between
groups in general health scores.
If there are differences found between groups,
certain statistical analysis can be performed to
adjust for this, for example multi-variate analysis.
It is sufficient to ascertain that this has been done,
unless you are of course a statitiscal wiz.
5. a) Eligibility criteria.  Of those entered into the trial,
were those included an appropriate sample capable
of answering the research question posed by the
authors?  Were there too many exclusions?  On
some occasions there are so many exclusions that
the sample bears little resemblance to the
population likely to reasonably present for therapy
in your own setting.  Note that it is worth checking
the authors conclusion to ascertain whether it is
suitably worded to take into consideration the
sample finally selected.  For example, in a trial of
manipulation and back pain conducted on adults,
the conclusion should specifically mention adults
as the study group.  The study cannot be generalised
to children.
b) Sample size calculations should be performed
before the study commences and mention of how
the figure was derived should be found in the
methods section of the paper.  The probability of
detecting a difference between groups when one
actually exists is called the power of the test.
Increasing the sample size increases the power.
6. All spectrums of disease should ideally be included
in the study, i.e. mild, moderate and severe.  If, for
example, only severe disease is included, the results
may make the therapy results appear artificially
poor.  However, if the purpose of the study is to look
only at a particular stage of disease (e.g. chronic)
then clearly this should be mentioned and the
conclusion confined to this stage.
7. Were the interventions used appropriate?
a) Were they sensible and described adequately?
The authors should in their introduction make out
a case for the use of the therapies under study.  The
use of the therapy should be inherently sensible,
biologically plausible and ethically sound.
All therapies should be defined clearly so that
another researcher could repeat the study and
have the therapies performed based on the original
description.  A fastidious trial uses only “pure”
and consistent forms of treatment, e.g. aspirin vs.
manipulation vs. acupunture, while a pragmatic
trial uses broader definitions e.g. chiropractic vs.
medicine vs. physiotherapy.  Regardless of the
approach a detailed definition of either should be
available in the methods section.
b) All therapies should be affordable, or if not then of
sufficient importance that it would be likely that
the cost could be reduced with mass introduction
(for example, hepatitis B vaccination), or the cost
met by Government (for example, simvastatin for
hypercholesterol-aemia).
c) Is the therapy available?  The therapy under
consideration should be generally available or
likely to be so.
d) The use of a placebo in trials of therapy is considered
important, but is controversial.  The advantage is
that placebo gives a base measure of improvement
by just providing help to the subject.  It may be (for
instance) that the therapies under study all deliver
the same level of improvement to the subjects and
that this level is the same as the placebo group.
How can the reader tell unless a placebo group is
included?
On the other hand there is the ethical question of
withholding therapy from those in the trial, and by
doing so possibly prolonging their pain and
suffering.
The epidemiologist in me says include the placebo,
while the few humanitarian bones that I have left
say leave it out.  What do you think?
e) A non-treatment group receives no therapy (placebo
or active).  The inclusion of such a group is
worthwhile to demonstrate the natural history of
the disease.  The same arguments arise as in the
placebo question.
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phenomenon fall closely to each other, while validity
is the degree to which the results of a measurement
correspond to the true state of the phenomenon being
measured.  For instance, palpation of the spine might
be highly reliable, but it may not correspond at all to
the existence of a manipulable lesion (validity).
11. Was normal defined?
In a trial measuring blood pressure, it is imperative
that normal ranges are known, so that abnormal can
also be defined.  Normal should be known from the
outset and defined in the study methods section.  For
instance, in a trial involving the measurement of
straight leg raising, is 60 or 90 degrees normal?  Or
in a trial measuring leg length discrepancy, should
we allow 5 mm or 5 cm tolerance as being within
normal limits?  As you can see normal is not always
an easy value to define.
12. Follow up
a) Was there sufficient follow up?
Terminating a trial before significant changes
take place constitutes a serious flaw in research
design.  For example, low back pain research has
often been criticised because intervention, and
particularly measurement of outcomes, was
terminated to early.  In the latter case, the question
often raised being “Is there a long lasting effect
from the treatment or is it only short lived?”
b) Adverse effects
The detailing of adverse effects in trials on therapy
is essential for the reader to be able to judge benefit
against risk.  All adverse effects should be reported
along with their frequency, severity and duration.
However, it must be recognised that therapy trials
are not good estimates of the risk of treatment.
They usually underestimate risk, particularly the
less common side effects.  Large cohort studies are
the design of choice.
13. How large was the treatment effect?
a) Was it statistically significant?
There is often a need to quantify the degree to
which chance variability may account for the
observed treatment results in a research study.
There are many statistical tests which are
appropriate for the particular situation.  Common
tests are the t-test and chi-square.  A commonly
reported measure of statistical significance is the
probability value or p-value.  By convention if the
p-value is less than 0.05 then the test is significant.
This means that there is less than or equal to a 1
in 20 chance of the observed value being observed
However, such groups, whether placebo or non-
treatment, are important in research to establish
baseline characteristics of the disease and to decide
whether therapy is useful.
8. Were the groups treated equally?  It is important to
ascertain whether the study groups were treated
equally.  For example, did the clinicians and staff
display the same amount of optimism for all therapies.
Did they all receive a reasonable amount of treatment
specific to the therapy?  For example, enough
manipulation or NSAID over a reasonable period of
time to be fair to the therapy.  Even simple matters
such as the availability of appointments for the
various therapies should be equal.
9. The three C’s.
Co-intervention, contamination, compliance.
a) Co-intervention.  After randomisation, patients
may receive a variety of interventions other than
the ones being studied.  If these occur unequally in
the two groups and affect outcomes, they can
introduce bias.  If very effective non-study
treatments are allowed at the physicians discretion,
co-intervention may be a big problem.  All such
co-interventions allowed should be mentioned in
the “Methods” section and should be minimal in
effect. For instance, if it was found that in a trial
on low back pain comparing manipulation and
mobilisation that one group were taking more
NSAID’s than the other, one might be very worried
about the effect.
b)Contamination.  This occurs when the control
group accidentally receives the active treatment.
c) Compliance with therapy is very important, and
the researchers should give detail of how they
established compliance, particularly where home
compliance is required for example, drugs or
exercises.
10. Instruments of measurement
Were they reasonable and adequate for all clinical
outcomes?  Measuring health and aspects of health is
a difficult task.  Many instruments of measurement
have been devised but few have been found to be
reliable and valid.  In therapy research, look to
ascertain that the instruments used have been found
to be reliable (inter-rater and intra-rater) and valid.
Also establish in your own mind that they are the
appropriate measures to answer the question posed in
the research.  It should be noted that reliability does
not mean validity.  Reliability is the extent to which
repeated measurements of a relatively stable
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by chance alone.  Remember though that 1 in 20
times this test will be wrong and show that an
observed value that is statistically significant,
when in fact it is not.  This is why repeated
research on the same question is often required.
More on this later in question 14c).  In brief,
statistical significance is important in showing
that the values observed in the study on therapy
were (on the balance of probability) either different
from group to group or not.  To illustrate, in a
hypothetical trial comparing manipulation and
mobilisation for the treatment of acute back pain,
it was found that the manipulation group were
back at work in a mean time of 3.2 days whereas
the mobilisation group were back at work in 3.6
days.  Can we say that such a difference is
statistically significant?  This will in fact depend
on the number of subjects in the trial.  If only 10
subjects were in each group it is unlikely, however
if there were 100 in each group it is very likely.
Statistical significance is important, always look
for it.  Of course it is not always necessary.  If the
difference in recovery time in the example above
was 3.2 days and 32 days, one hardly needs a
statistical tests to demonstrate a difference between
reasonably sized groups.
b) Was it clinically significant?
An outcome may be statistically significant but
not clinical significant.  For instance, in the
example in 13a) above, if the mean recovery time
was 3.2 days and 3.24 days respectively and the
trial involved a large number of subjects, say
3000, then it is likely that the resultant difference
of 0.04 days would reach statistical significance,
but it is doubtful that such a small difference could
be said to be clinically significant.
A meaningful difference in treatment effect should
be defined by the authors at the outset.
c) Biological plausibility?
Even if there is a statistically and clinically
significant difference found in the results of the
study, the reader is well advised to consider whether
the results are actually biologically plausible.  There
may be some other factors at play that are not
immediately obvious giving a spurious result.
14. How precise was the estimate of effect?
a) Was the sample size sufficient?
The estimate of sample size is based on a few facts
and a relatively straight forward mathematical
calculation.  Determination of sample size is also
known as power analysis or determining the power
of the study.  Suffice to say that the greater the
sample size the greater the power of the study.
b) Were confidence intervals given?
Confidence intervals are statistical values which
estimate the variability of the result.  They define
an upper limit and a lower limit with an associated
probability.  The most commonly used confidence
interval is that associated with a 95% probability.
Let us illustrate this rather abstract notion with an
example.  In a fictitious study, serum calcium was
measured before and after manipulation of the
spine.  Forty three male patients were tested and
the mean pre-manipulative serum calcium was
measured at 9.9 mg/dL, with a standard deviation
of 0.66.  The mean of the post-manipulation group
was 9.5 mg/dL.  The researchers wanted to know
whether the results in this group of manipulated
subjects were in fact different from the normal
population (pre-manipulated state).  The 95%
confidence limits were calculated and showed that
we can be 95% confident that the true post
manipulation mean falls between 9.3 and 9.7 mg/
dL.  So the conclusion is that the post manipulative
group probably fall outside the population pre-
manipulation mean and are indeed different.
c) Was there any data dredging?
Data dredging is the performance of a myriad of
hypothesis tests on a data set after the study has
been completed in the hope of finding some result
that is statistically significant.  The safest way to
perform such post hoc tests is to reduce the p-value
commensurate with the number of post-hoc tests
performed.  Remember from 13a) above that,
based on the 0.05 p-value, 1 in every 20 tests will
provide a spuriously false positive result.
Therefore, by dividing the 0.05 value by the
number of extra post hoc tests we can be assured
that the chances of a spurious result are not
increased.
For example, if 100 post hoc tests are to be
performed, the p-value will change from 0.05 to
0.0005.  Always check for data dredging.  Authors
should have established what tests were to be
performed prior to commencement of the trial.
15. Were the limitations of the study discussed?
It is important that the authors discuss adequately the
limitations of their study.  Such limitations should
then accord with the wording of the conclusion.  A
major limitation in the study (even if admitted) may
render the conclusion invalid.
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16. Were there any other biases operating, and if so in
what direction?
There are many potential biases in therapy research.
If you find one then determine whether the bias
operates to make the results appear better or worse,
and judge for yourself what potential impact this may
have on the conclusion.
17. Can the results be applied to my patient care?
Therapy research conducted in a tertiary setting such
as a hospital may attract a very different type of
patient to those who attend a local clinic.  Careful
analysis of the patient demographics, prognostic
data and general health indices will assist in
determining equivalence.  The point is, the patients
who were in the trial may bear little resemblance to
your own, therefore generalising the results to your
own clinic may be invalid.
18. Is the treatment efficacious?  Is it effective?
A therapy may be shown in a research study to be
efficacious.  That is under the circumstances it was
trialled it has been shown to work.  However, it may
not be effective in the real world.  For instance,
epidural injections may be shown to be effective for
the treatment of chronic low back pain, but if the
general public by and large do not want to be injected
into the spine then the treatment is not effective.
Further, if chiropractic treatment was ever to shown
to be efficacious in the treatment of asthma, would
the public at large choose chiropractic treatment over
the use of cheaper, convenient and more readily
available drugs.
CONCLUSION
Now, go to it and try reviewing the next therapy paper
(preferably a randomised controlled trial) that interests
you.  Having performed your critical appraisal of the
paper, try and conclude whether on balance you are
inclined to accept the conclusions drawn by the authors.
Does it actually answer the research question posed?
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